Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers
about
A comprehensive overview of targeted therapy in metastatic renal cell carcinomaSunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis.Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma.Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomasBrain natriuretic peptide precursor (NT-pro-BNP) levels predict for clinical benefit to sunitinib treatment in patients with metastatic renal cell carcinomaCongestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials.Sunitinib and other targeted therapies for renal cell carcinoma.Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities.Relationships between Chromosome 7 Gain, MET Gene Copy Number Increase and MET Protein Overexpression in Chinese Papillary Renal Cell Carcinoma Patients.A phase I study of BMS-690514 in Japanese patients with advanced or metastatic solid tumors.The distinct signatures of VEGF and soluble VEGFR2 increase prognostic implication in gastric cancer.Biomarkers for tyrosine kinase inhibitors in renal cell cancer.The VEGF pathway in cancer and disease: responses, resistance, and the path forward.Endothelial follicle stimulating hormone receptor in primary kidney cancer correlates with subsequent response to sunitinib.PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GISTDiffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinomaBasic research in kidney cancer.Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis.Predictive molecular biomarkers to guide clinical decision making in kidney cancer: current progress and future challenges.Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma.GLI2 expression levels in radical nephrectomy specimens as a predictor of disease progression in patients with metastatic clear cell renal cell carcinoma following treatment with sunitinib.Platelet-Derived Growth Factor (PDGF)/PDGF Receptors (PDGFR) Axis as Target for Antitumor and Antiangiogenic Therapy.Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells.Sunitinib improves chemotherapeutic efficacy and ameliorates cisplatin-induced nephrotoxicity in experimental animals.Change in platelet count as a prognostic indicator for response to primary tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma.Quantitative insight in utilizing circulating angiogenic factors as biomarkers for antiangiogenic therapy: systems pharmacology approach.Predictive role of tissue-based molecular markers in patients treated with sunitinib for metastatic renal cell carcinoma.Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study.Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.Acute renal failure during the "off" period after sunitinib administration: possible mechanism of vascular endothelial growth factor cascade hyperactivation.Efficacy of anti-VEGF agents in the treatment of elderly hepatocellular carcinoma: a systematic review.Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain.Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib.Metastatic Renal Cell Carcinoma Presenting as a Bleeding Gastric Polyp
P2860
Q24606852-2D1C48CB-8739-4658-9A5E-F88B52439E48Q33404547-4752D750-53F1-43B1-BCD7-D7AEE4E67D88Q33474188-41B3CFF7-B24D-4831-8FCB-C52543717461Q33587610-8F80CFFE-E083-4FD5-B85E-AAFAC0CFED6EQ33692402-83C39FE7-7D01-4FB7-A067-EC4DF7FFF9CDQ34554398-C583E034-DF0D-44D5-9E9C-21753A058E89Q34621802-F9D48016-AD9D-4C51-9ECA-BE4678453976Q35104052-A282A42C-C9E3-42E5-8213-CE6A87A1BE00Q35861046-579780F7-BB83-4A94-8218-F9BE69FBCFD7Q36275492-D3BDFF78-8082-4A89-8726-16EE4DB6B072Q36420167-CD0CBFCC-28BF-423C-87C9-FFC690F81369Q36450612-C83CFF1E-F1BD-4440-A1B7-03468C4C08CDQ36526512-EDBA421F-2796-4581-A62F-AB3711365DF4Q37294895-E8794CFA-F2CD-457F-9CF1-ECADE71213EFQ37366059-40BE0845-5F05-4896-BA48-3C62857A5870Q37559090-3C9ED4E4-BABF-4235-B092-72320B69CA52Q37899447-9E418889-C5B1-430B-AB92-E069FAB0605EQ38071132-21541BF4-D6E3-4815-9498-BA37C8F77A2FQ38402997-91BCF9C4-CCE4-4504-9158-0421C49CAD89Q38543085-E519D8B0-E54E-4056-BA27-70AA728303E1Q38747792-B317CD38-239B-4D44-80D6-873D021CB42CQ38974204-222F9093-BCA1-4C97-9635-3E61A50F32C1Q39348852-8D5890E5-6100-43FF-9082-98494DFB60F7Q39396441-15090490-1DC9-4B6C-B633-7CD7F5F96754Q39676953-A357184B-040E-4A55-BF90-65F0FE71E5C2Q40836247-7ACA1E4A-F98B-4880-8432-011254E5CBA8Q42418396-29128F43-0ED2-4D7C-AE82-17DAE4948A36Q43725656-7B29D465-F919-40BB-8C96-8926F5EFE305Q44049376-57368B56-D99F-4F45-A283-2295ECF7E239Q45093247-C32EE1D9-AD3B-4A0B-A328-31B85F9F46C4Q45745688-D9F57A57-E571-48E2-9C17-8E16539E0738Q46024539-C0485C67-9CA8-4A89-A17A-6BCC6D0052BFQ46233598-3FA79482-3D37-46C5-BC0E-73AAB065D5CBQ54626855-E07005B2-DBD4-4904-86B8-EF7320B180C8Q57060788-884074A6-4A42-4173-9258-5534CF8A6363
P2860
Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Sunitinib treatment for patien ...... nd plasma angiogenesis markers
@ast
Sunitinib treatment for patien ...... nd plasma angiogenesis markers
@en
type
label
Sunitinib treatment for patien ...... nd plasma angiogenesis markers
@ast
Sunitinib treatment for patien ...... nd plasma angiogenesis markers
@en
prefLabel
Sunitinib treatment for patien ...... nd plasma angiogenesis markers
@ast
Sunitinib treatment for patien ...... nd plasma angiogenesis markers
@en
P2093
P2860
P356
P1433
P1476
Sunitinib treatment for patien ...... nd plasma angiogenesis markers
@en
P2093
Alexandros H Kortsaris
Charalambos Andreadis
Despoina Mouratidou
Konstantinos T Papazisis
Loukas F Kontovinis
Panagiota Touplikioti
P2860
P2888
P356
10.1186/1471-2407-9-82
P407
P577
2009-03-12T00:00:00Z
P5875
P6179
1051473159